Mark Fidock

2.1k citations

32 papers · 1.6k indexed · 1 hit paper · h-index 20

Molecular Biology top 10%
Immunology top 10%
Cellular and Molecular Neuroscience top 5%
Physiology top 10%
Cardiology and Cardiovascular Medicine

Co-authors: Nicola Robas Emma J. Mead Steven A. Trim Janet J. Maguire Rhoda E. Kuc Anthony P. Davenport Clare Gardner Beate Peter
Topics: Receptor Mechanisms and Signaling (11 papers)Neuropeptides and Animal Physiology (5 papers)Asthma and respiratory diseases (5 papers)
Cited by: Biological Psychiatry Immunology and Allergy Cellular and Molecular Neuroscience
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry PLoS ONE
Partner nations: United Kingdom United States Sweden

In The Last Decade

Mark Fidock

32 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact of a five-dimensional framework on R&D productivity at AstraZeneca

2018 271 citations Paul Morgan, Dean G. Brown et al. Nature Reviews Drug Discovery profile →

Peers

Countries citing papers authored by Mark Fidock

Since Specialization

Citations

This map shows the geographic impact of Mark Fidock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Fidock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Fidock more than expected).

Fields of papers citing papers by Mark Fidock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Fidock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Fidock. The network helps show where Mark Fidock may publish in the future.

Co-authorship network of co-authors of Mark Fidock

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Fidock. A scholar is included among the top collaborators of Mark Fidock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Fidock. Mark Fidock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Eosinophil-derived neurotoxin: A biologically and analytically attractive asthma biomarker 2021 ·PLoS ONE ·Bart P. F. Rutten,Simon Young,Magdalena Rhedin,Marita Olsson,Nisha Kurian,(unknown),Augusta Beech,Mark Fidock,Paul Newbold,Dave Singh,Adam Platt,(unknown)	27
2	The commutability of enzyme linked immunosorbent assays for the quantification of serum eosinophil-derived neurotoxin (EDN) 2021 ·Journal of Immunological Methods ·Bart P. F. Rutten,Simon Young,(unknown),(unknown),Mark Fidock,Paul Newbold,Dave Singh,Adam Platt,(unknown)	2
3	A novel automated SARS-CoV-2 saliva PCR test protects a global asymptomatic workforce 2021 ·Scientific Reports ·(unknown),Maryam Clausen,Rebecca Halpin,(unknown),Kang Cai,Oona Delpuech,Alexander Kohlmann,O. Magnusson,Ruth March,Daniel O’Neill,(unknown),James Sherwood,(unknown),(unknown),(unknown),(unknown),Daniel T. Wise,Mark Fidock	1
4	Impact of a five-dimensional framework on R&D productivity at AstraZenecabreakdown → 2018 ·Nature Reviews Drug Discovery ·Paul Morgan,Dean G. Brown,Simon Lennard,Mark J. Anderton,J. Carl Barrett,Ulf G. Eriksson,Mark Fidock,Bengt Hamrén,Anthony Johnson,Ruth March,James Matcham,Jerome T. Mettetal,David Nicholls,Stefan Platz,Steve Rees,Michael Snowden,Menelas N. Pangalos	271
5	Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms 2015 ·Brain Behavior and Immunity ·Shahin Aeinehband,Philip Brenner,Sara Ståhl,Maria Bhat,Mark Fidock,Mohsen Khademi,Tomas Olsson,Göran Engberg,Jussi Jokinen,Sophie Erhardt,Fredrik Piehl	62
6	Macrophage Migration and Invasion Is Regulated by MMP10 Expression 2013 ·PLoS ONE ·Megan Y. Murray,Timothy P. Birkland,Jonathan D. Howe,Andrew D. Rowan,Mark Fidock,William C. Parks,Jelena Gavrilović	79
7	Therapy with TLR7 Agonists Induces Lymphopenia: Correlating Pharmacology to Mechanism in a Mouse Model 2012 ·Journal of Clinical Immunology ·(unknown),(unknown),(unknown),Peter Colman,Frances Burden,Carl Laxton,Nigel Horscroft,(unknown),Débora F. Rodrigues,(unknown),Jonathan R. Heyen,Mark Fidock,Mike Westby,Helen Bright	20
8	The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691) 2011 ·Clinical Pharmacology & Therapeutics ·Mark Fidock,(unknown),Carl Laxton,(unknown),(unknown),(unknown),Peter Colman,Vinay Kumar,(unknown),Katherine Wright,Subasree Srinivasan,Khurram Rana,Charles Craig,Nigel Horscroft,Manos Perros,Michael Westby,Robert O. Webster,Elna van der Ryst	64
9	Quantitative UPLC-MS/MS analysis of the gut microbial co-metabolites phenylacetylglutamine, 4-cresyl sulphate and hippurate in human urine: INTERMAP Study 2011 ·Analytical Methods ·Anisha Wijeyesekera,Philip A. Clarke,Magda Bictash,Ian Brown,Mark Fidock,Thomas Ryckmans,Ivan Kok Seng Yap,Queenie Chan,Jeremiah Stamler,Paul Elliott,Elaine Holmes,Jeremy K. Nicholson	28
10	A differential role for ceramide kinase in antigen/FcɛRI-mediated mast cell activation and function 2011 ·Clinical & Experimental Allergy ·Christopher A. Hewson,(unknown),(unknown),Mark Fidock	4
11	A Chemical Genomic Approach Identifies Matrix Metalloproteinases as Playing an Essential and Specific Role in Xenopus Melanophore Migration 2009 ·Chemistry & Biology ·Matthew L. Tomlinson,Pingping Guan,Richard J. Morris,Mark Fidock,Martin Rejzek,Carla García‐Morales,Robert A. Field,Grant N. Wheeler	42
12	Anti-inflammatory modulation of chronic airway inflammation in the murine house dust mite model 2008 ·Pulmonary Pharmacology & Therapeutics ·Kristina Ulrich,(unknown),Roddy Walsh,(unknown),Mark Fidock,Sasha Sreckovic,David Lamb,Garry J. Douglas,Michael Yeadon,Christelle Perros-Huguet,Sue Evans	41
13	Allosteric effects of antagonists on signalling by the chemokine receptor CCR5 2007 ·Biochemical Pharmacology ·(unknown),(unknown),Mark Fidock,(unknown),Philip G. Strange	13
14	Interactions between the Mas-Related Receptors MrgD and MrgE Alter Signalling and Trafficking of MrgD 2005 ·Molecular Pharmacology ·Sandra Milasta,John D. Pediani,(unknown),Steven A. Trim,Michael D. Wyatt,Peter J. Cox,Mark Fidock,Graeme Milligan	57
15	Identification and cellular localisation of NPW1 (GPR7) receptors for the novel neuropeptide W-23 by [125I]-NPW radioligand binding and immunocytochemistry 2004 ·Brain Research ·Gurminder Singh,Janet J. Maguire,Rhoda E. Kuc,Mark Fidock,Anthony P. Davenport	29
16	High-Affinity Interactions between Human α1A-Adrenoceptor C-Terminal Splice Variants Produce Homo- and Heterodimers but Do Not Generate the α1L-Adrenoceptor 2004 ·Molecular Pharmacology ·Douglas Ramsay,Ian Carr,John D. Pediani,Juan F. López‐Giménez,Richard J. Thurlow,Mark Fidock,Graeme Milligan	54
17	MrgX2 Is a High Potency Cortistatin Receptor Expressed in Dorsal Root Ganglion 2003 ·Journal of Biological Chemistry ·Nicola Robas,Emma J. Mead,Mark Fidock	203
18	Isolation and differential tissue distribution of two human cDNAs encoding PDE1 splice variants 2002 ·Cellular Signalling ·Mark Fidock,(unknown),Jerry Lanfear	26
19	IDENTIFICATION OF A HISTAMINE H₄RECEPTOR ON HUMAN EOSINOPHILS—ROLE IN EOSINOPHIL CHEMOTAXIS 2002 ·Journal of Receptors and Signal Transduction ·(unknown),(unknown),Stephen Jenkinson,Ronald P. Gladue,Shane Foo,Steven A. Trim,Beate Peter,Mike Trevethick,Mark Fidock	159
20	Regulation of Intracellular Ca²⁺ in Response to Muscarinic and Glutamate Receptor Agonists During the Differentiation of NTERA2 Human Embryonal Carcinoma Cells into Neurons 1996 ·European Journal of Neuroscience ·Paul E. Squires,Jane A. Wakeman,(unknown),(unknown),Mark Fidock,Peter W. Andrews,Mark J. Dunne	25

About Mark Fidock

Mark Fidock is a scholar working on Cellular and Molecular Neuroscience, General Dentistry and Immunology and Allergy, having authored 32 papers that have together received 1.6k indexed citations. Recurring topics across this work include Receptor Mechanisms and Signaling (11 papers), Neuropeptides and Animal Physiology (5 papers) and Asthma and respiratory diseases (5 papers). The work is most often cited by research in Biological Psychiatry (52 citations), Immunology and Allergy (112 citations) and Cellular and Molecular Neuroscience (329 citations). Mark Fidock has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include Nicola Robas, Emma J. Mead, Steven A. Trim, Janet J. Maguire, Rhoda E. Kuc, Anthony P. Davenport, Clare Gardner, Beate Peter, Ronald P. Gladue and Stephen Jenkinson. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact